Browsing tag:

BMI


On September 10, 2014, The U.S. Food and Drug Administration (US FDA) approved Contrave (naltrexone hydrochloride and bupropion hydrochloride extended-release tablets) for anti-obesity treatments in combination with a reduced-calorie diet and exercise. Contrave is distributed by Takeda Pharmaceuticals America Inc. of Deerfield, Illinois for Orexigen Therapeutics, Inc. of La Jolla, California. The FDA approved the[…]

Read More

The dramatic approval of Lorcaserin, now known by the trade name Belviq, was announced on June 27, 2012. Lorcaserin, CAS# 846589-98-8, is the first drug to be approved for weight loss in over twelve years. This announcement, made by representatives from both Easai and Arena Pharmaceuticals was a welcome one for researchers, patients and practitioners[…]

Read More

This website uses cookies. By using our site, you agree to our terms of service